- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06690398
Étude multicentrique sur la lumatepérone pour le traitement de l'irritabilité associée aux troubles du spectre autistique chez les patients pédiatriques
Une étude multicentrique randomisée, en double aveugle, contrôlée par placebo, pour évaluer l'efficacité et l'innocuité de la lumatepérone dans le traitement de l'irritabilité associée aux troubles du spectre autistique chez les patients pédiatriques âgés de 5 à 17 ans
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study will be conducted in 3 phases:
- Screening Period (up to 14 days) during which patient eligibility will be assessed.
- Double-blind Treatment Period (DBTP) (6 weeks) during which all patients will be randomized in a 1:1:1 ratio to receive either lumateperone high dose, lumateperone low dose, or placebo as a once daily dose.
- Safety Follow-up Period (1 week) during which all patients will return to the clinic for a safety follow-up (SFU) visit approximately 1 week after the last dose of study drug.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Study Contact
- Numéro de téléphone: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Lieux d'étude
-
-
-
Belgrade, Serbie, 11000
- Recrutement
- Institute of Mental Health Serbia
-
Belgrade, Serbie, 11000
- Recrutement
- Institute of Mental Health Serbia 1
-
Belgrade, Serbie, 11070
- Recrutement
- Clinic of Neurology and Psychiatry for Children and Youth
-
Niš, Serbie, 18000
- Recrutement
- University Clinical Center NIS
-
-
-
-
Alabama
-
Dothan, Alabama, États-Unis, 36303
- Recrutement
- Harmonex Neuroscience Research
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85006
- Recrutement
- Southwest Autism Research and Resource Center
-
-
California
-
Anaheim, California, États-Unis, 92805
- Recrutement
- Advanced Research Center Inc
-
Oceanside, California, États-Unis, 92056
- Recrutement
- Excell Research Inc
-
Redlands, California, États-Unis, 92373
- Recrutement
- Inland Psychiatric Medical Group Inc
-
Upland, California, États-Unis, 91786
- Complété
- Buena Park Research
-
West Covina, California, États-Unis, 91790
- Recrutement
- Next Level Clinical Trials, LLC
-
-
Colorado
-
Colorado Springs, Colorado, États-Unis, 80910
- Complété
- MCB Clinical Research Centers LLC
-
-
Florida
-
Fort Myers, Florida, États-Unis, 33901
- Suspendu
- Royal Palm Clinical Research
-
Gainesville, Florida, États-Unis, 32607
- Recrutement
- Sarkis Clinical Trials
-
Jacksonville, Florida, États-Unis, 32258
- Recrutement
- Green Leaf Clinical Trials
-
Miami, Florida, États-Unis, 33176
- Recrutement
- Anchor Medical Research LLC
-
Miami, Florida, États-Unis, 33176
- Recrutement
- Links Clinical Trials
-
Miami, Florida, États-Unis, 33125
- Recrutement
- Columbus Clinical Services LLC
-
Miami, Florida, États-Unis, 33175
- Recrutement
- Diverse Clinical Research LLC
-
Miami, Florida, États-Unis, 33166
- Recrutement
- South Florida Research Phase I-IV
-
Miami Gardens, Florida, États-Unis, 33169
- Recrutement
- The Angel Medical Research Corporation
-
West Palm Beach, Florida, États-Unis, 33407
- Recrutement
- Health Synergy Clinical Research
-
-
Georgia
-
Savannah, Georgia, États-Unis, 31405
- Recrutement
- CenExeli Research LLC
-
-
Illinois
-
Elgin, Illinois, États-Unis, 60123
- Recrutement
- Revive Research Institute
-
Springfield, Illinois, États-Unis, 62701
- Suspendu
- Southern Illinois University School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Complété
- Massachusetts General Hospital
-
Worcester, Massachusetts, États-Unis, 01655
- Recrutement
- UMass Memorial Healthcare
-
-
Missouri
-
Saint Charles, Missouri, États-Unis, 63304
- Recrutement
- Midwest Research Group
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89128
- Recrutement
- Vector Clinical Trials
-
-
Ohio
-
Garfield, Ohio, États-Unis, 44125
- Recrutement
- Charak Center for Health and Wellness
-
Westlake, Ohio, États-Unis, 44145
- Complété
- Westlake Brain Health
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Access Clinical Trials
-
-
Texas
-
Beaumont, Texas, États-Unis, 77701
- Recrutement
- REX Clinical Trials LLC
-
Flower Mound, Texas, États-Unis, 76028
- Complété
- North Pointe Psychiatry
-
Houston, Texas, États-Unis, 77089
- Recrutement
- Kaleidoscope Clinical Research
-
Plano, Texas, États-Unis, 75093
- Recrutement
- AIM Trials
-
Richmond, Texas, États-Unis, 77407
- Recrutement
- Perceptive Pharma Research
-
-
Virginia
-
Petersburg, Virginia, États-Unis, 23805
- Recrutement
- Clinical Research Partners, LLC
-
-
Washington
-
Bellevue, Washington, États-Unis, 98007
- Recrutement
- Northwest Clinical Research Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
All patients must have a legally authorized representative LAR (eg, parent or legal guardian) who is willing and able to be responsible for the safety and well-being of the patient, provide information about the patient's condition, and accompany the patient to study visits.
-
Able to provide consent as follows:
- The patient's LAR must provide written, informed consent.
- When developmentally appropriate based on Investigator judgment, the patient should provide written assent.
-
Male or female patients 5 to 17 years of age. Currently, only patients aged 13 to 17 years will be eligible for enrollment.
-
Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of ASD as confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL);
-
ABC-I subscale score of >18 at Screening and Baseline;
-
CGI-S score > 4 with respect to irritability associated with ASD at Screening and Baseline.
Exclusion Criteria:
-
Has a primary psychiatric diagnosis other than ASD. Exceptions include:
- Attention Deficit Hyperactivity Disorder (ADHD). If a patient is taking medication(s) for ADHD, they must be on a stable treatment regimen of these medication(s) for 30 days prior to screening and the treatment regimen is expected to remain stable throughout the study. This must be confirmed by the Investigator and noted in the source records.
- Mild and moderate intellectual disability based on Investigator judgment and DSM-5 criteria (severe and profound intellectual disability are excluded).
-
History or current diagnosis of Rett syndrome or Fragile X syndrome;
-
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during their participation in the study or
- At Screening, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 since the Screening Visit;
- At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening; or
- The patient is considered to be an imminent danger to themselves or others.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
Placebo |
Matching Placebo administered orally once daily |
|
Expérimental: Lumateperone high dose
Lumateperone 42 mg for patients ages 13-17 years old |
Lumateperone administered orally once daily |
|
Expérimental: Lumateperone low dose
Lumateperone 21 mg for patients ages 13-17 years old |
Lumateperone administered orally once daily |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Aberrant Behavior Checklist - Irritability (ABC-I)
Délai: Week 6
|
The ABC-I subscale contains 15 items which rate symptoms on a scale ranging from 0 (not at all a problem) to 3 (severe). |
Week 6
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Clinical Global Impression-Severity (CGI-S)
Délai: Week 6
|
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). |
Week 6
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Intra-Cellular Therapies, Inc. Clinical Trial, Intra-Cellular Therapies, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ITI-007-601
- ITI-007-601 (Autre identifiant: Janssen Research & Development, LLC)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .